Entos, Inc., a San Diego, CA-based creator of a platform combining AI-driven technology and automated synthetic development to design small-molecule therapeutics, closed a $53m Series A financing.
The round was led by Coatue and Catalio Capital Management, with participation from OrbiMed and Sequoia Capital as well as existing investors Nexus Ventures and Freeflow. As part of the funding, Aaron Weiner, Managing Director and Head of Healthcare at Coatue, and R. Jacob Vogelstein, Ph.D., Co-Founder and Managing Partner of Catalio, joined Entos’ Board of Directors that includes Tom Miller, Co-Founder and Chief Executive Officer, Fred Manby, Co-Founder and Chief Technology Officer, and Naren Gupta, Co-Founder and Managing Director of Nexus Venture Partners.
Entos Nets $53 Million to Accelerate AI-Driven Therapies biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.